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Abstract. Cancer stem cells play an important role in 
carcinogenesis and resistance to treatment and may lead to 
metastasis. The isolation of circulating stem cells involves 
cell sorting based on the presence of cell surface markers. 
Many surface markers such as CD133, c-Kit, SOX, OCT4 
and TWIST have been reported. In the present study, we 
determined the expression of different stem cell markers 
and their variation in expression at different stages of the 
treatment process. Samples of EDTA blood were collected 
from metastatic colorectal cancer patients, and circulating 
cancer stem cells were isolated for the analysis of the expres-
sion of stem cell markers using RT-PCR. These findings 
were correlated with the response to therapy. All statistical 
analyses were performed using the GraphPad Prism 5.03 
software. Significant differences were found in the expression 
levels of the markers CD133, SOX2, OCT4 and TWIST1. No 
differences were found in c-Kit expression. Correlation in 
the expression levels of most of the markers was observed. 
Expression of CD133, OCT4, SOX2 and TWIST1 had a 
predictive value for colon cancer behavior. Evaluation of this 
stem cell gene expression panel may be useful for predicting 
the response during the process of treatment, and the relative 
easy access to samples facilitates this method. Moreover the 
correlation between CD133 and TWIST1 expression may be 
associated with tumor regrowth and metastatic relapse.
Introduction
Tumors derived from epithelial tissues as lung, prostate, colon 
or breast are the most prevalent in industrialized countries. 
Colorectal cancer is one of the most common causes of cancer-
related mortality worldwide. For colorectal cancer, surgical 
resection of the tumor is commonly the first therapeutic 
action with curative intent. However, ~50% of patients develop 
metastatic disease which is incurable with current treatments. 
Although the median overall survival has increased as a result 
of the improvement in systemic therapies such as new chemo-
therapy agents and monoclonal antibodies, the median overall 
survival has reached a plateau at 24 months. Therefore, one 
of the main challenges in colorectal cancer is to develop new 
strategies to inhibit disease progression (1,2).
The stem cell hypothesis postulates that cancers, as they 
occur in normal tissues, consist of at least two types of cell 
populations: cancer stem cells (CSCs) and adult stem cells. 
CSCs exhibit all of the characteristics of stem cells: the 
capability of self-renewal, unlimited proliferation potential, 
multi-line differentiation and the capability to form new cancer 
stem cells and adult cancer stem cells through asymmetric divi-
sion. It has been hypothesized that CSCs play a role in tumor 
chemoresistance. They have also been termed cancer initiating 
cells as they retain the ability to form colonies, and are also 
responsible for tumor recurrence and refractoriness (3-9). 
It has been suggested that colorectal cancer is caused by an 
alteration in the normal homeostasis of stem cells (Fig. 1). 
The standard procedure for isolating circulating stem 
cells involves cell sorting of the cell subpopulation based on 
the presence of cell surface markers. Many of these surface 
markers have been reported to be present in CSCs. The expres-
sion of these markers change depending on the organ that is 
consider. One of the putative markers highly specific in colon 
cancer is CD133 (also known as prominin-1). The CD133 gene 
is located on chromosome 4p15.32 and encodes a cell surface 
glycoprotein consisting of 5 transmembrane domains and 2 
large glycosylated extracellular loops. Yet, the function of 
CD133 has not been established to date. An association between 
levels of CD133 and the prognosis of colorectal cancer patients 
have been established. Several authors have reported that high 
expression of CD133 is associated with poor prognosis and 
distant metastasis, while another study indicates it is an inde-
pendent factor. Initially identified in hematopoietic stem cells, 
CD133 is a shared cancer stem cell marker in multiple solid 
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tumors including brain, breast, lung, liver, prostate, pancreas, 
medulloblastoma and melanoma (10-24).
c-Kit, also called KIT, CD117 or c-Kit receptor, is a cyto-
kine receptor expressed on the surface of several types of 
stem cells. c-Kit was first identified as the cellular homolog 
of the feline sarcoma viral oncogene V-kit. Altered forms of 
this receptor may be associated with certain types of cancer. 
This protein is a type 3 transmembrane receptor for mast cell 
growth factor, also known as stem cell factor (MGF). The 
kit gene encodes the human homolog of the proto-oncogene 
c-Kit. Mutations in this gene are associated with gastrointes-
tinal stromal tumors, testicular seminoma, mast cell disease, 
melanoma, acute myeloid leukemia, and benign disease such 
as piebaldism. Multiple transcript variants encoding different 
isoforms have been found for this gene (25).
OCT4 is a commonly used synonym for POU5F1 (POU 
class 5 homeobox 1). It is a homeodomain transcription factor 
of the POU family. This protein is critically involved in the 
self-renewal of undifferentiated embryonic stem cells; thus, it 
is commonly used as a marker of undifferentiated cells. OCT4 
expression must be strictly regulated; excess or default causes 
cell differentiation. The OCT4 transcription factor is initially 
active as a maternal factor in the oocyte but remains active 
in embryos throughout the preimplantation period. OCT4 
expression is associated with the undifferentiated phenotype 
and tumors. OCT4 can form a heterodimer with SOX2; thus, 
these two proteins bind DNA together (26,27).
OCT4 and SOX2 transcription factors are essential for 
normal pluripotent cell development and maintenance. They 
are also known as reprogramming genes, inducing an embry-
onic stem cell-like state. SOX2 plays a critical role in cell fate 
determination, differentiation and proliferation; is involved 
in cancer events such as invasion and metastasis, and plays a 
role in conferring a low differentiation phenotype in tumors. 
TWIST1, a master regulator of embryonic morphogenesis, plays 
an essential role in metastasis. Ectopic expression of TWIST1 
results in loss of E-cadherin-mediated cell-cell adhesion, acti-
vation of mesenchymal markers, and induction of cell motility, 
suggesting TWIST contributes to metastasis by promoting an 
epithelial-mesenchymal transition (EMT) (28-30).
For epithelial tumors, EMT is consider to be a crucial event 
in the metastatic process, which involves the disruption of 
epithelial cell homeostasis and the acquisition of a migratory 
mesenchymal phenotype allowing cells to travel to the site of 
metastasis formation without being affected by conventional 
treatment. Assuming metastasis requires dissemination of 
tumor stem cells showing EMT, it seems likely that this type 
of cell is detectable among circulating tumor cells found in 
cancer patients (31).
The objective of our study was to determine the expres-
sion of markers of CSCs in circulating tumor cells (CTCs) in 
the peripheral blood of colon cancer patients, and assess the 
pathway expression at various time points during treatment in 
respect to the response of the disease to chemotherapy.
Materials and methods
We enrolled 29 metastatic colorectal cancer patients. Eligibility 
patient criteria were as follows: age ≥18 years of age, clinical 
stage IV based on the International TNM classification (40), 
performance status of 0-2, and the presence of no other malig-
nancies. All of the patients were treated with fluoropyrimides. 
A second group of 16 healthy volunteers, matched for age, 
were used as the control group. All patients and volunteers 
signed informed consent forms. This study was approved by 
the Ethics Committee for Clinical Research of Galicia, Spain 
(CEIC Galicia: 2010/238).
Samples of EDTA blood (10 ml) were collected for detec-
tion of circulating CSC markers. Blood samples were evaluated 
for expression of c-Kit, CD133, SOX2, OCT4 and TWIST1 
before and during chemotherapy.
In the patient group, samples were collected at 3 different 
time points during therapy: prior to chemotherapy; before the 
second cycle of treatment, and finally before the fifth cycle of 
treatment. The patient response was evaluated following the 
Response Evaluation Criteria In Solid Tumors (RECIST 1.1) 
(39) and was confirmed by computed tomography (CT) 
according to 4 categories: complete response (CR), partial 
response (PR), stable disease (ED) and progressive disease 
(PD).
Samples were centrifuged at 2,000 x g, for 10 min; the 
serum phase was separated and frozen at -80˚C. Buffy coat 
was collected and processed with lysis (ammonium chloride, 
Tris, ddH2O) and washed with PBS. The dry pellet was 
maintained at -80˚C until RNA isolation. RNA was purified 
using the QIAamp RNA Blood Mini kit (Qiagen Inc., USA), 
according to the manufacturer's instructions. Complementary 
DNA (cDNA) was synthesized with random hexamer primers 
(Deoxynucleoside Triphosphate Set; Roche, Germany) with 
10 mM MgCl2, MuLV reverse transcriptase, PCR buffer, 
RNAse inhibitor and random hexamers (Applied Biosystems, 
USA). The resulting cDNA was stored at -20˚C until further 
use.
Quantitative RT-PCR analysis was carried out with 
SYBR-Green Master Mix (Applied Biosystems), using 
Applied Biosystems 7500 Real-Time PCR system according to 
the manufacturer's instructions. Primers for c-Kit and GAPDH 
were designed with Vector NTI Advance™ 11 (Invitrogen), and 
primers for CD133, SOX2, OCT4 and TWIST1 were designed 
with Primer3 software (version 0.4.0; Biology Workbench) 
(Table I). To avoid the influence of genomic contamination, 
forward and reverse primers for each gene were located in 
different exons. PCR was performed using a final volume of 
20 µl with SYBR-Green PCR Master Mix, using 1 µl cDNA. 
Figure 1. Scheme of the theoretical behavior of stem cells in cancer, their 
maintenance and transformation to produce distant metastases.
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Cycling conditions consisted of 95˚C for 10 min, followed by 
40 cycles at 95˚C for 15 sec and 60˚C for 1 min each. A melting 
curve was then obtained.
Relative gene expression levels were determined using the 
quantitative curve method. Quantitative normalization of cDNA 
in each sample was performed using GAPDH gene expression as 
an internal control. Target gene messenger RNA (mRNA) levels 
were expressed as ratios to GAPDH mRNA levels. RT-PCR 
assays were carried out in duplicate for each sample, and the 
mean value was used for calculation of the mRNA expression 
levels.
Data are presented as median, range and mean ± standard 
deviation. Significance between two groups was determined 
by an unpaired two-tailed Student's t-test. P<0.05 was 
considered to indicate a statistically significant difference. 
Spearman's correlation coefficient non-parametric measure 
of statistical dependence between two variables was used; a 
perfect Spearman correlation of +1 or -1 occurs when each 
of the variables is a perfect monotone function of the other. 
All statistical analyses were carried out using GraphPad Prism 
5.03 software. 
Results
Patient characteristics. We evaluated the expression of CSC 
markers in the peripheral blood of 29 colon cancer patients. 
The patients had stage IV disease and consisted of 16 males 
and 13 females with a median age of 63 years (range 42-85). 
Three patients dropped out of the study due to disease 
progression.
Distribution of the localization of the tumors is as follows: 
6 were situated in the ascending colon, 2 were in the transverse 
colon, 6 were in the descending colon, 5 were in the sigmoid 
colon, 8 were in the rectum, and the sites was unknown for 
2 patients diagnosed at other hospitals. All of the cases were 
adenocarcinomas: 9 well differentiated, 19 moderately differen-
tiated and 1 poorly differentiated. 
The control group included 16 volunteers with a median age 
of 60 years (range 42-83). 
We analyzed the CEA values at three different time points 
during the sample collection, but no statistical differences were 
noted, although a reduction in the levels of CEA was noted 
when patients demonstrated a response to chemotherapy.
Expression of the various markers. DNA obtained from cells 
isolated from the peripheral blood samples was analyzed by 
RT-PCR. The signal expression of stem cell markers, c-Kit, 
CD133, SOX2, OCT4 and TWIST1, in the patients were 
compared with the healthy control group.
The expression of the markers was also assessed in colon 
tumor tissue samples, following the same procedure to obtain 
DNA for RT-PCR analysis.
When we compared the patients not yet treated with 
chemotherapy with the controls, significant differences in the 
expression of CD133, SOX2, OCT4 and TWIST1 (p=0.0002; 
p=0.0182; p=0.0217; p=0.0031, respectively) (Fig. 2) were 
noted. Expression of c-Kit was not significantly different.
When we analyzed the same marker levels in the periph-
eral blood in the patients following administration of the 
first cycle of chemotherapy and prior to the administration 
of the second, the results obtained were similar. There were 
significant differences in the expression levels of the same 
markers: CD133 (p=0.008), SOX2 (p=0.036), OCT4 (p=0.04) 
and TWIST1 (p=0.0002). No difference was found in c-Kit 
expression (Fig. 2).
We next divided the patients according to their response to 
treatment. There were two groups: one group included patients 
with no change, and another group exhibited PR or CR to 
treatment. We found differences in the expression pattern 
of the markers in the patients ‘in progression’ compared to 
those ‘with response’. In the patient with tumor progression, 
Figure 2. Expression of c-Kit, CD133, SOX2, OCT4 and TWIST1 in the DNA 
of cells isolated from the peripheral blood of patients prior to chemotherapy 
(columns with horizontal lines, left) and following the first dose of chemo-
therapy (columns with oblique lines, middle), compared with healthy donors 
(columns with squares, right). Prior to chemotherapy, apart from c-Kit, all 
of the markers demonstrated differences between the patients and controls; 
levels were higher than in the healthy donors, but they were reduced after 
treatment. There were no significant differences between the controls and 
patients who received one dose of chemotherapy. When comparing patients 
before and after chemotherapy, the levels of markers were significantly 
reduced, in particular TWIST1. Data were normalized to establish the com-
parison. *Indicates differences with statistical significance between patients 
and controls. ***Indicates differences with statistical significance between 
patients and controls at P<0.001.
Table I. Sequences of the specific primers designed to perform 
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we found differences in the levels of all markers, including 
c-Kit. The differences were significant: for c-Kit (p=0.0046), 
for CD133 (p=0.0001), for SOX2 (p=0.0042), for OCT4 
(p=0.0094) and for TWIST1 (p<0.001). In the patient group 
with no progression, there were no differences in expression 
levels when compared with the controls (Fig. 3).
In addition to the comparison between patients and 
controls, we compared the different groups of patients in 
regards to response to therapy.
When comparing patients prior to chemotherapy with 
patients who had tumor progression after 4 cycles of treatment, 
differences only in the expression of TWIST1 (p<0.0001) were 
noted. When we compared the patients prior to treatment with 
those showing a response after 4 cycles of chemotherapy, 
differences in the levels of CD133 (p=0.0002) and OCT4, 
(p=0.0073) were noted.
Comparing patients following administration of 4 cycles 
of treatment with those who were administered only one dose, 
the patient group with tumor progression had high expres-
sion levels of all the markers with significant P-values [c-Kit 
(p=0.0011), CD133 (p=0.01), SOX2 (p=0.02), OCT4 (p=0.04)
and TWIST1 (p<0.0001)]. In the case of the group who showed 
respond to therapy, there were no significant differences.
Finally, we compared the patients after the fourth cycle of 
chemotherapy with tumor progression and without progres-
sion; expression of all markers demonstrated significant 
differences excluding SOX2.
Correlation between markers. After evaluation of marker 
expression, we applied the Spearman's test to ascertain the 
correlation between them. In the patients prior to chemo-
therapy, we found a negative correlation between c-Kit and 
SOX2 (r=0.5, p=0.03), while positive correlations were noted 
between CD133 and SOX2 (r=0.6, p=0.01), CD133 and OCT4 
(r=0.6, p=0.01), CD133 and TWIST1 (r=0.9, p=0.002), and 
SOX2 and OCT4 (r=0.8, p=0.0003).
In the patients who received one dose of chemotherapy 
a correlation was noted between CD133 and SOX2, OCT4 
and TWIST1, with the following values: CD133 and SOX2 
(r=0.55, p=0.04); CD133 and OCT4 (r=0.88, p<0.0001), SOX2 
and OCT4 (r=0.65, p=0.01). Finally, there was no correlation 
between TWIST1 and CD133, TWIST1 and SOX2, TWIST1 
and OCT4 and between c-Kit and the rest of the markers.
In the patients who received 4 cycles of chemotherapy 
with tumor progression, a positive correlation was noted only 
between OCT4 and TWIST1 (r=0.89, p=0.0002) (Fig. 4). 
In the same patient group but without tumor progression, a 
significant correlation was found between c-Kit and CD133 
(r=0.55, p=0.001), c-Kit and OCT4 (r=0.47, p=0.04), c-Kit and 
TWIST1 (r=0.49, p=0.03), CD133 and OCT4 (r=0.53, p=0.02), 
CD133 and TWIST1 (r=0.61, p=0.006), OCT4 and TWIST1 
(r=0.68, p=0.001).
Discussion
In the present study, we found significant differences in the 
levels of various stem cell markers (CD133, SOX2, OCT4 and 
TWIST1) correlated with colon cancer behavior. There was a 
reduction in expression when the tumors were responsive to 
the chemotherapy, and in contast, increased levels were noted 
when there was no response to treatment. Thus, the expression 
of these markers predicted the behavior of the tumor.
Research has focused on the study of tumor stem cells, in 
particular, in regards to the expression of markers to facilitate 
the identification of putative stem cells in tumors. Most of 
them are developed in tissue from a surgical tumor resection 
using a histological study. According to the cancer stem cell 
theory, CSCs are initiators of metastasis. Thus, our objective 
was to isolate them in peripheral blood. This procedure was 
used previously, and it affords the advantages of simplicity 
and easy accessibility to patient samples, without biopsy. 
Figure 3. Expression of c-Kit, CD133, SOX2, OCT4 and TWIST1 in the 
DNA of cells isolated from the peripheral blood of patients prior to chemo-
therapy (column with dots, left) and after the fourth dose of chemotherapy 
(column with horizontal lines, middle), compared with healthy controls 
(columns with oblique lines, right). The levels of all markers were increased 
in patients with disease progression when compared with the controls, 
indicating no response to chemotherapy and tumor spread. Notable were 
the levels of CD133 and TWIST1, a colon stem cell marker and epithelial-
mesenchymal transition marker, respectively. Conversely, there were no 
differences between the levels of markers between patients responsive to 
chemotherapy and the controls. Data were normalized to establish the com-
parison. *Indicates differences with statistical significance between patients 
and controls. ***Indicates differences with statistical significance between 
patients and controls at P<0.001.
Figure 4. Correlation between levels of expression of OCT4 and TWIST1 in 
patients who received 4 cycles of chemotherapy. Spearman's correlation was 
applied to determine the grade of association between the two variables. The 
data obtained, 0.89, indicates a high level of association between OCT4 and 
TWIST1, two of the markers of immature stem cells, suggesting transforma-
tion of the cancer stem cells into a mesenchymal state, to facilitate migration 
and invasion into other tissues.
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RT-PCR has been widely used for the detection of CSCs in 
the peripheral blood for a variety of cancer types. RT-PCR is 
extremely sensitive, less subjective and can be automated, but 
its specificity depends on the cancer marker used (32-34).
In the present study, expression of c-Kit and CD133 was 
found in primary tumors, and CD133 expression was consis-
tently higher in all colon cancer cases as compared to the 
controls, thus ruling out the possibility that CD133+ cells came 
from bone marrow. This difference in expression could be used 
as a biomarker, since the level in patients was almost 2-fold when 
compared to that in the controls. The level was decreased in 
patients responsive to treatment, whereas in patients exhibiting 
disease progression an increase in levels was noted, due to an 
increase in the cell numbers in the tumor. There are many puta-
tive markers of cancer stem cells. Expression of these markers 
change depending on the specific tumor. Yet, at present, there is 
no doubt that CD133 is an effective stem cell marker for colon 
cancer. There are discrepancies concerning the pattern and 
frequency of CD133 expression in colon cancer. Horst et al (13) 
and Kojima et al (14) reported that CD133 expression is 
localized on glandular-luminal surface of colorectal cancer. 
However, Chun-Yan et al (8) showed that CD133 expression is 
located not only on the apical membrane but also on the basal 
surface of tumor cells, both in the invasive front. Nevertheless, 
we must consider the heterogeneous pathways and that CD133 
expression levels are variable depending on the study.
Our data demonstrated that levels of SOX2 and OCT4 
were highly correlated in patients and their trend was similar 
to CD133. It is well known that SOX2 and OCT4 are associ-
ated with the maintenance of stem cells, and play a critical role 
in the determination, differentiation and proliferation of stem 
cells, explicating the correlation between them and CD133. 
This positive correlation means that there is an increase in the 
number of stem cells and all the mechanisms implicated in 
proliferation and maintenance are activated (28,29-35).
The levels of the three markers, CD133, SOX2 and OCT4, 
were higher than in the controls in all cases, indicating that 
this was not due to maintenance of the physiological stem 
cells and is in relation with circulating cancer stem cells. 
Furthermore, their levels were reduced in those patients who 
were responsive to treatment, and increased in patients who 
were not responsive. We also observed a statistically significant 
correlation of the three markers at all sample collection points. 
This was in accordance with Saigusa et al (36) who reported 
that expression of the 3 genes (CD133, SOX2 and OCT4) was 
identified in residual CSCs and was associated with distal 
recurrences and poor disease-free survival which is linked to 
cancer cells that survive radical treatment, in support of the 
theory of metastasis due to stem cells. Our data indicate that 
CD133, OCT4, SOX2 had a predictive value for colon cancer 
behavior, and the expression may be useful for predicting the 
evolution of the treatment process.
Similar results were found for TWIST1 which regulates 
EMT in vertebrates. TWIST1 is highly expressed in several 
tumor types and its upregulation is considered an unfavorable 
prognostic factor in colorectal cancer. We demonstrated that 
the levels of TWIST1 exhibited the same trend as that of the 
other markers, but compared to all the markers, it indicated 
a favorable response to treatment. This suggests that it is a 
good indicator of disease progression and response to therapy. 
Furthermore, TWIST2 was highly correlated with the other 
markers. This indicated that EMT occurs in stem cells in 
order to facilitate circulation in the peripheral blood, which is 
a protective mechanism for transit to distant organs. OCT4 and 
SOX2 are required for their maintenance, and once the cells 
reached a distant site they again began to show more specific 
markers. TWIST1 had predictive value for colon cancer 
behavior, and its correlation with OCT4 and the other markers 
may be useful for predicting the evolution of the treatment 
process (37).
The gene c-Kit, or stem cell factor, was the only marker 
exhibiting a different trend. In patients prior to treatment and 
after one dose of chemotherapy, the levels of c-Kit were lower 
in the patients when compared with that in the controls, while 
after the fourth dose of treatment the levels increased. This 
suggests that expression of c-Kit in colon tumors is rare; thus, 
it is not a marker of choice in the colon. These findings are 
in accordance with Friederichs et al (38). Yet, the increased 
expression after several dose of chemotherapy can indicate 
a change in receptor expression pathway of stem cells, or an 
alteration in the tyrosine-kinase receptors.
In conclusion, expression of CD133, OCT4, SOX2 and 
TWIST1 had a predictive value for colon cancer behavior. 
Evaluation of the expression of these stem cell gene markers 
may be useful for predicting the evolution of the treatment 
process, and the relative easy access to samples facilitates 
this method. Moreover, the correlation between CD133 and 
TWIST1 expression may be associated with tumor recur-
rence and metastatic relapse. These findings open new lines 
of research for the development of techniques for the study 
of circulating cancer stem cells and have implications in the 
research of the progression of colon cancer and have predictive 
value in translational oncology.
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